UK at JP Morgan 2025: breaking UK news roundup

Nxera Pharma reports significant progress on its partnered muscarinic agonist portfolio with Neurocrine Biosciences, including plans for Phase 3 schizophrenia trials and multiple Phase 2 studies in 2025.

Johnson & Johnson has agreed to acquire Intra-Cellular Therapies for $14.6 billion, adding its innovative schizophrenia and bipolar treatment CAPLYTA® to J&J's neuroscience portfolio, along with a promising pipeline of therapies targeting neuropsychiatric and neurodegenerative disorders.

A new biotech venture co-founded by Khurem Farooq is advancing best-in-class oral and injectable therapies for obesity and cardiometabolic disorders, backed by $411 million in funding from leading global investors.

GSK has announced the acquisition of IDRX-42, a next-generation KIT tyrosine kinase inhibitor (TKI). This $1.15 billion deal strengthens GSK’s portfolio in gastrointestinal cancers, aiming to address critical gaps in current therapies.